Grace Therapeutics, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 1.94 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 40.81M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company’s lead product candidate is the GTX-104, an injectable formulation developed to treat aneurysmal subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to enhance neurological symptoms of Ataxia-Telangiectasia (A-T); and GTX-101, a topical bio adhesive film-forming bupivacaine spray for the treatment of pain associated with postherpetic neuralgia (PHN). The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. Grace Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
Details
| Name | Grace Therapeutics, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 5 |
| Founded | 2002 |
| Ceo | Prashant Kohli |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| Isin | US00439U1043 |
| Cusip | 00439U104 |
| Cik | 0001444192 |
| Sic | 2834 |
| Share Class | Class A Shares |
Key executives
| Name | Title |
|---|---|
| Prashant Kohli | Chief Executive Officer and Director |
| Amresh Kumar Ph.D. | Vice President of Program Management |
| Carrie D'Andrea | Consultant |
| Robert J. DelAversano CPA | Vice President of Finance and Principal Financial and Accounting Officer |
| Dr. R. Loch MacDonald M.D., Ph.D. | Member of Scientific Advisory Board and Chief Medical Officer |
Contact
| Address | 103 Carnegie Center, Suite 300, Princeton, New Jersey 08540, United States |
| Phone | 609 322 1602 |
| Website | https://www.gracetx.com |